A two-peptide research blend of BPC-157 and TB-500 combining gastric pentadecapeptide and thymosin beta-4 pathway tools.
Pre-loaded with a typical Wolverine vial. Change any value to match what you actually have.
What published research and laboratory protocols actually document for Wolverine. Where a compound has no single microgram figure, we say so rather than inventing one.
| Reported amount | Frequency | Route | Where this figure comes from |
|---|---|---|---|
| 250 mcg – 500 mcg | daily | subcutaneous or near-injury subcutaneous (as discussed in secondary sources) | Secondary research protocols for BPC-157 component (commonly cited) Animal literature uses varied routes including intraperitoneal and oral in some models; human standardized dosing is not established. |
| 2 mg – 5 mg | loading phase 2x weekly, then less frequent maintenance (as often described secondarily) | subcutaneous | Secondary research protocols for TB-500 / TB4-fragment component Loading-versus-maintenance patterns are common in informal guides; thymosin beta-4 clinical wound studies used protocol-specific TB4 dosing not identical to research-fragment charts. |
People searching this page also look for: wolverine peptide dosage per day, wolverine peptide dosage, wolverine blend peptide dosage, wolverine peptide stack dosage, wolverine peptide dosage chart, wolverine stack peptide dosage, ss-31 peptide dosage swolverine, wolverine stack peptide dosage chart.
Wolverine is a research-supply nickname for a combination of BPC-157 and TB-500 (a synthetic fragment analog related to thymosin beta-4). It does not denote a new chemical entity; it is a dual-peptide formulation intended to cover two overlapping but distinct repair literatures in one vial.
BPC-157 has an extensive preclinical record in rodent models of tendon, ligament, muscle, and gut injury, with proposed actions on angiogenesis, fibroblast behavior, and nitric oxide-related pathways. Thymosin beta-4 / TB-500 literature emphasizes actin sequestration, cell migration, angiogenesis, and dermal healing, including some early clinical wound-care explorations of TB4. Direct high-quality trials of the fixed combination are sparse compared with the single-agent animal data.
Educational dosing must split the blend into BPC-157 mcg and TB-500 mcg using the labeled ratio. Research-use-only language applies throughout: these are literature-linked reference ranges and formulation explanations, not treatment plans.
BPC-157 is reported in animal studies to support tendon outgrowth, cell survival, and migration via pathways that include FAK-paxillin signaling, with broader cytoprotective and angiogenic themes across injury models. TB-500 draws on thymosin beta-4 biology: binding G-actin, facilitating cytoskeletal reorganization, and promoting progenitor cell motility and new vessel growth in repair environments. The blend hypothesis is spatial-temporal complementarity, local tissue stabilization plus enhanced cell trafficking, rather than dual occupancy of one receptor.
tendon and ligament healing models · muscle injury · wound healing · angiogenesis · sports-medicine translational research
Musculoskeletal and sports-medicine researchers comparing peptide tool compounds in soft-tissue injury models are the primary audience. Regenerative labs interested in angiogenesis and cell migration also evaluate the parent pathways. Formulation scientists assess dual-peptide stability and ratio selection.
Store lyophilized blend cold and dry. After reconstitution, refrigerate promptly, avoid contamination, and follow the supplier's beyond-use date for combined peptide solutions.
Wolverine is the minimal BPC-157 + TB-500 pair. Glow adds GHK-Cu; Klow adds GHK-Cu and KPV. Researchers escalate complexity only when the question requires copper-matrix or inflammatory-fragment coverage. Keep component-level records even when the brand name is a single word.
The questions people actually search for, answered plainly.
There is no official single dose. Calculate BPC-157 and TB-500 separately from the vial ratio. Secondary sources often discuss BPC-157 around 250-500 mcg/day and TB-500 in multi-mg loading amounts a few times weekly. Verify against your label and primary literature.
2-5 mL bacteriostatic water is typical depending on total milligrams. More diluent improves precision for the smaller BPC-157 fraction. Label the bottle with mg/mL total and the fraction map.
BPC-157 is frequently framed as daily in secondary protocols, while TB-500 is often not daily after a loading phase. A blend draw once daily may over- or under-deliver TB-500 relative to those informal schedules. Adjust using component math.
Effective charts show units -> total mcg -> BPC mcg -> TB-500 mcg. Example: if a vial is 5 mg BPC-157 + 5 mg TB-500 in 2 mL, each 0.1 mL contains 250 mcg of each peptide. Different ratios need different charts.
Preclinical soft-tissue models measure histologic and biomechanical endpoints over days to several weeks. No controlled human timeline validates the branded blend. Avoid promising personal recovery intervals.
Half-life attaches to each peptide, not the nickname. Both are generally short-acting peptides; frequency patterns in protocols are practical conventions, not direct half-life copies.
Adding GHK-Cu yields a Glow-like profile; adding KPV as well approaches Klow. Each addition should be hypothesis-driven. Document every mcg to keep research notes interpretable.
The research rationale pairs BPC-157's injury-site cytoprotective/angiogenic themes with thymosin beta-4-related cell migration and cytoskeletal remodeling. Complementary mechanisms are a hypothesis supported by separate literatures, not by large combination RCTs.
Primary literature on Wolverine. Open access where available.
Every citation above was programmatically checked against the NCBI PubMed database. Titles shown are the official indexed titles, not paraphrases.
Our support assistant walks through reconstitution, syringe units, storage, and how to read a Certificate of Analysis. Free, no account.
Read the guides